From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

The most amazing bear dossier of the year so far - Hindenburg on Enochian (and the link to UK listed Genflow)

By Tom Winnifrith | Sunday 5 June 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


The dossier below from bear raiders Hindenburg is the stuff of movies. You could not make it up. It strikes me that Nasdaq listed Enochian (ENOB) is a zero as the man behind it, Serhat Gumrukcu, is a lifelong criminal now facing a possible death sentence in the US as he is charged with having a whistleblowing former associate murdered. There is a UK angle which I discuss in bearcast later, the unclear links between the CEO of Genflow Biosciences (GENF), Endochian, Dandrit Inc and Serhat.  Enjoy.

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 17:43:50